

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, 38/17, 31/70, A61P 13/12	A2	(11) International Publication Number: WO 00/07624 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/JP99/04238 (22) International Filing Date: 5 August 1999 (05.08.99) (30) Priority Data: 10/233499 6 August 1998 (06.08.98) JP (71) Applicant (for all designated States except US): TEIJIN LIMITED [JP/JP]; 6-7, Minamihommachi 1-chome, Chuo-ku, Osaka-shi, Osaka 541-0054 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): SASAKI, Satoshi [JP/JP]; Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). SUMI, Yoshihiko [JP/JP]; Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). HUGHES, Reginald, Colin [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London, Greater London NW7 1AA (GB). (74) Agents: ISHIDA, Takashi et al.; A. Aoki, Ishida & Associates, Toranomom 37 Mori Building, 5-1, Toranomom 3-chome, Minato-ku, Tokyo 105-8423 (JP).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PHARMACEUTICAL COMPOSITION HAVING INHIBITORY EFFECT ON OVERPRODUCTION AND ACCUMULATION OF EXTRACELLULAR MATRIX		
(57) Abstract A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biological activity of galectin-3, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, diabetic nephropathy or tissu fibrosis, as well as the use of said compound for the production of pharmaceuticals for the above-mentioned use, and a method for inhibition of the overproduction and accumulation of the extracellular matrix.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTION

PHARMACEUTICAL COMPOSITION HAVING INHIBITORY EFFECT ON
OVERPRODUCTION AND ACCUMULATION OF EXTRACELLULAR MATRIX

5 FIELD OF INVENTION

The present invention relates to a preventive or
therapeutic pharmaceutical composition having an
inhibitory effect on the overproduction and the
accumulation of extracellular matrix, said composition
10 comprising as an active ingredient a compound that
inhibits the biological activity of galectin-3.

BACKGROUND ART

Galectin-3 is a protein that has a molecular weight
of about 30 Kd belonging to the family of β -galactoside-
15 binding protein and is a lectin that widely occurs on the
cell surface, the cytoplasm and the nucleus of the tissue
(see, for example, Barondes, S. H. et al., J. Biol. Chem.
(1994) 296: 20807-20810, Hughes, R. C. Glycobiology
(1994) 4: 5-12, Wang, L. et al., Biochem. Biophys. Res.
20 Commun. (1995) 217: 292-303, and the like). It is known
that galectin-3 binds to a suitable sugar chain portion
of glycoprotein present on the cell surface or in the
extracellular matrix (ECM) and thereby activates
inflammatory cells such as neutrophils, basophils, or
25 macrophages to promote the production of cytokines from
these cells (see, for example, Sato, S. et al., J. Biol.
Chem. (1994a) 269: 4424-4430, Liu, F. T. Immunol. Today
(1993) 14: 486-490), or to suppress the apoptotic death
of T cells by its overexpression (see Yang, R-Y, H. et
30 al., Proc. Natl. Acad. Sci. U.S.A. (1996) 93: 6737-6742),
and it is believed to be an important protein responsible
for inflammatory and immunological reactions.

Furthermore, galectin-3 is also known to play an
important role in the formation and repair of the tissue
35 since it is highly expressed during the damage repair
period in the rat lung-injured model induced by X-ray
irradiation (see Kasper, M. et al., J. Pathol. (1996)

179: 309-316) and it is possibly playing an important role in the formation of kidney tissue in humans during the embryonic stage (see Winyard, P. J. D. et al., J. Am. Soc. Nephrol. (1997) 8: 1647-1657).

5 The overproduction and the accumulation of extracellular matrix (ECM) such as collagen is believed to be an important factor for the pathogenesis of the fibrosis of tissues such as liver, kidney, lung, heart, pancreas, artery, gastrointestinal tract, thyroid, 10 salivary gland, and skin (see Okada, H. et al., Kidney Int. (1996) 49: Supple. 54: S-37-S-38, Coker, R, K. et al., Eur. Respir. J. (1998) 11(6) : 1218-1221 and the like). ECM is also involved in the maintenance of homeostasis of cellular functions together with the 15 support of parenchymal cells at the physiological conditions. When minor injuries are inflicted to tissues, the repair of the injured tissues is completed by the treatment of the injured tissues by phagocytic cells in the process of inflammatory and repair 20 reactions, the subsequent regeneration of parenchymal cells, and the reconstruction of the supportive substrate, ECM. However, when the injuries are severe or persist for a long time, the overproduction and the accumulation of ECM will cause severe damages in the 25 functions of each tissue. In the liver, for example, lymphocytes and macrophages infiltrate to the periphery of the injured liver cells, and these cellular infiltrates and Kupfer cells or vascular endothelial cells and the like produce cytokines such as PDGF, TGF- β , 30 etc., which then activate Ito cells, a kind of ECM-producing cells. The activated Ito cells proliferate and produce ECM in an excess amount in the Disse's space thereby to cause hepatic fibrosis or hepatic cirrhosis that are said to be a terminal status of the hepatic 35 diseases. In the kidney glomeruli, for example, cytokines such as PDGF and TGF- β are produced from the

cells that have infiltrated into the periphery of the injured kidney cells or endothelial cells in the glomeruli etc. to activate the mesangium cells that are a kind of ECM-producing cells. The activated mesangium cells proliferate while themselves also producing cytokines such as PDGF and TGF- β together with an excessive amount of ECM, creating factors that cause various glomerular diseases, for example, chronic glomerular nephritis, including IgA nephropathy, diabetic nephropathy, glomerular sclerosis and the like. In the interstitial tissue of the kidney also, due to the activation of myofibroblasts, a kind of ECM-producing cells, and the epithelial cells of urinary tubules, these cells excessively produce ECM in the interstitial region of the urinary tubules and form fibrosis of the tubulo-interstitium thereby significantly reducing the renal function. Thus, the ECMS that were overproduced and accumulated in each tissue physically constrain the cellular functions of each cell and substitute for the functional unit of each tissue to cause severe functional disorders of each organ.

For the above-mentioned diseases, adrenal cortical steroids, immunosuppressive agents, anti-platelet agents, anti-coagulants, anti-fibrinolytic agents, ACE inhibitors, and the like are currently used, but no drugs exhibit satisfactory efficacy on the overproduction and the accumulation of ECM, and there is a strong need for agents that have a novel mechanism of action.

Although galectin-3 has been highly expressed at the injured site of the tissue in the rat lung-injured models induced by X-ray irradiation, a model of pulmonary fibrosis, it has not been elucidated whether it can regulate the overproduction and the accumulation of ECM such as collagen and the survival of the mesangium cells that are a kind of ECM-producing cells. Accordingly, it is not known whether the inhibition of the action of galectin-3 can inhibit the overproduction and the

accumulation of ECM and thereby it has a therapeutic and/or preventive usefulness for glomerular nephritis, diabetic nephropathy or tissue fibrosis.

DISCLOSURE OF INVENTION

5 It is an object of the present invention to provide a pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of ECM, said composition comprising as an active ingredient a compound that inhibits the biological activity of galectin-3.
10 Furthermore, it is an object of the present invention to provide a therapeutic or preventive agent comprising said compound inhibiting the biological activity of galectin-3 and a pharmaceutically acceptable carrier. In particular, it is an object of the present invention to
15 provide a therapeutic or preventive agent based on a novel mechanism of action of inhibiting the biological activity of galectin-3 for the diseases caused by the overproduction and the accumulation of ECM such as glomerular nephritis, diabetic nephropathy or tissue
20 fibrosis for which no conventional drugs show satisfactory inhibitory effects.

Considering the state of art of the conventional technology, the present inventors have carried out intensive study and have found that galectin-3 is a
25 molecule that can regulate the overproduction and the accumulation of ECM such as collagen and a molecule that can regulate the survival of the mesangium cells which is a kind of ECM-producing cells, and also have found that substances that inhibit the biological activity of
30 galectin-3 can regulate the overproduction and the accumulation of ECM such as collagen, and have thereby completed the present invention.

Thus, the present invention provides a therapeutic or preventive pharmaceutical composition having an
35 inhibitory effect on the overproduction and the accumulation of ECM, said composition comprising as an active ingredient a compound that inhibits the biological

activity of galectin-3, and a pharmaceutically acceptable carrier.

This indicates that compounds that inhibit the biological activity of galectin-3 can be a therapeutic or preventive agent of glomerular nephritis, diabetic nephropathy or tissue fibrosis of which cause is the overproduction and the accumulation of extracellular matrix.

BRIEF EXPLANATION OF THE DRAWINGS

Figure 1 shows a variation in the expression of galectin-3 in the anti-Thy-1.1 antibody-induced rat nephritis model.

A: the kidney of the rats who received no anti-Thy-1.1 antibody, B: day 8 after the administration of anti-Thy-1.1 antibody, C and D: day 14 after the administration of anti-Thy-1.1 antibody.

The asterisk in the figure shows a representative macula densa region, m a representative mesangium region, c a representative crescent body-forming region, the closed arrow tail a representative distal urinary tubule, the closed arrow a representative proximal urinary interstitial tubule, and the open arrow a representative infiltrated macrophage or fibroblast.

Figure 2 shows a variation in the expression of galectin-3 in the UUO rat model.

A: contralateral kidney, B: obstructed kidney

The asterisk in the figure shows a representative macula densa region, the closed arrow tail a representative distal urinary tubule, and the open arrow a representative infiltrated macrophage or fibroblast.

Figure 3 shows the activity of galectin-3 to inhibit the cellular death of the mesangium cells.

Figure 4 shows the activity of galectin-3 to promote the production of collagen type IV by the rat mesangium cells.

Figure 5 shows the suppression by galectin-3 binding-inhibiting glycoprotein of the activity of

galectin-3 to promote the production of collagen type IV production by the rat mesangium cells.

Figure 6 shows the suppression by galectin-3 binding-inhibiting sugar of the activity of galectin-3 to promote the production of collagen type IV production by the rat mesangium cells.

DETAILED DESCRIPTION

Compounds that inhibit the biological activity of galectin-3 for use in the present invention include, for example, the following:

(1) Anti-galectin 3 antibody: mouse anti-galectin 3 monoclonal antibody (for example, an antibody described in Lui, F. T., Et al., J. Biol. Chem. (1996) 35: 6073-6079);

(2) Inhibitors of galectin-3 binding: sugars to which galectin-3 can bind such as Gal β 1-4Glc, Gal β 1-4GlcNAc, Fuc α 1-2Gal β 1-4Glc, Gal α 1-3Gal β 1-4GlcNAc, Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, Fuc α 1-2Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-3(Fuc α 1-4)GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-3GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)Glc, Fuc α 1-2(GlcNAc α 1-3)Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc, NeuNAc α 2-3Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc, NeuNAc α 2-6Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-3(NeuNAc α 2-6)GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-3GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-3GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4Glc, Gal β 1-4GlcNAc β 1-6(Gal β 1-3GlcNAc β 1-3)Gal β 1-4Glc, Gal β 1-4GlcNAc β 1-6(Gal β 1-4GlcNAc β 1-3)Gal β 1-4Glc, Gal β 1-4GlcNAc β 1-6(Gal β 1-4GlcNAc β 1-2)Man α 1-6(Gal β 1-4GlcNAc β 1-2Man α 1-3)Man β 1-4GlcNAc, Gal β 1-4GlcNAc β 1-2Man α 1-6(Gal β 1-4GlcNAc β 1-4(Gal β 1-4GlcNAc β 1-2)Man α 1-3)Man β 1-4GlcNAc, GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, Gal α 1-3Gal β 1-4GlcNAc β 1-

(3) Compounds that inhibit the incorporation of galectin-3 into the cell: those which inhibit the biological activity of galectin-3 by acting on galectin-3 receptor or the cells that contain galectin-3 receptor, including, for example, antagonists of galectin-3 receptor, or anti-galectin 3 receptor antibody, AGE or AGE receptor or fragments thereof (see Vlassara, H. et

al., Molecular Medicine (1995) 1: 634-646, and the like);

(4) Compounds that inhibit the transfer of galectin-3 into the cell: inhibitors of galectin-3 transporter protein;

5 (5) Compounds that inhibit the biological activity of galectin-3 in the nucleus or in the cytoplasm: galectin-3 binding proteins that bind to galectin-3 in the nucleus or in the cytoplasm, or derivatives of nucleic acid or fragments thereof, or compounds that
10 inhibit their binding; and

(6) Compounds that inhibit the expression or secretion of galectin-3: antisense of the galectin-3 gene, compounds that inhibit the function of the promoter region of the galectin-3 gene, compounds that inhibit the
15 transfer of proteins in the cell such as brefeldin A.

Compounds that inhibit the biological activity of galectin-3 for use in the present invention can be formulated to make pharmaceutical compositions having an inhibitory effect on the overproduction and the
20 accumulation of ECM by blending said compounds as active ingredients and pharmaceutically acceptable carriers. The pharmaceutical composition may be therapeutic or preventive agents comprising said compounds and pharmaceutically acceptable carriers.

25 Diseases caused by the overproduction and the accumulation of ECM include glomerular nephritis, diabetic nephropathy or tissue fibrosis and they also include glomerular nephritis, diabetic nephropathy or tissue fibrosis that are derived from the abnormal
30 proliferation of the mesangium cells.

As used herein, pharmaceutically acceptable carriers can include those that are identical with the excipients mentioned below. The amounts blended of a compound that inhibits the biological activity of galectin-3 and a
35 carrier, without any limitation, follow the dosage of the active ingredient mentioned below, and can be widely selected. The amount of a compound that inhibits the

- 9 -

biological activity of galectin-3 is usually 1 to 70 percent by weight and preferably 5 to 50 percent by weight in the total composition.

5 The composition thus obtained can be provided as an oral preparation such as a soft capsule, a hard capsule, a tablet, granules, powders, a suspension, a liquid, a syrup etc., an injection, a suppository, or an external preparation using a suitable excipient in a known method.

10 Such excipients include, for example, plant oils (for example, corn oil, cotton seed oil, coconut oil, almond oil, peanut oil, olive oil, and the like), oily esters such as glyceride oils of middle chain fatty acids, mineral oil, glycerin esters such as tricaprylin and triacetin, alcohols such as ethanol, physiological
15 saline, propylene glycol, polyethylene glycol, vaseline, animal fats, cellulose derivatives (crystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose), polyvinylpyrrolidone, cyclodextrin, dextrin, lactose, mannitol, sorbitol,
20 starch and the like.

The dosage of the active ingredient, though depends on the degree of the disease and the age of the patient etc., is about 0.01 mg to 1000 mg per day per capita, preferably 1 mg to 200 mg per day per capita. It is
25 desired that the formulations satisfy such conditions.

EXAMPLES

The present invention will now be explained with reference to the following examples, but the present invention is not limited to these examples in any way.

30 Example 1. Variation in the expression of galectin-3 in the rat nephritis model induced by anti-Thy-1.1 antibody

Rabbit anti-Thy-1.1 antiserum was obtained by immunizing rabbits subcutaneously on the back with Thy-
35 1.1 antigen purified from rat thymus cells. The rat nephritis model induced by anti-Thy-1.1 antibody was prepared by intravenously administering to the tails of

- 10 -

Sprague-Dawley rats 0.25 ml of the above rabbit anti-Thy-1.1 antiserum diluted 2-fold in phosphate buffered saline together with 0.25 ml of normal rabbit complement (Sigma) according to the method of Okuda et al. (Okuda S., et al., J. Clin. Invest. (1990) 86: 453-462). The rats were sacrificed on day 3, 7, and 14 after the administration of the antibody, and the kidney was extracted from each rat after perfusion with phosphate buffered saline. The extracted kidney was fixed in 4 % (w/v) phosphate buffered formalin, embedded in paraffin, and tissue sections for immunostaining were prepared. The immunostaining of the tissue sections was carried out by using affinity-purified rabbit anti-galectin-3 antibody as the primary antibody, peroxidase-labeled goat anti-rabbit antibody (Sigma) as the secondary antibody, and DAB (Sigma: DAB Tablet) as the chromogenic substrate.

The result of immunostaining of the tissue sections is shown in Figure 1. It was confirmed that in the rats who received no anti-Thy-1.1 antibody, a small quantity of galectin-3 was present in the distal urinary tubule and the macula densa region of the glomerulus, while in the rats who received anti-Thy-1.1 antibody, a large quantity of galectin-3 was observed in the distal and the proximal urinary tubule and the glomerulus on day 8 and 14 after the antibody administration. It was also confirmed that on day 14, infiltrated macrophage and fibroblasts were coexistent with galectin-3 in the pre-fibrotic region of the tubulo-interstitium. This finding confirmed that the expression of galectin-3 is increased at the time of pathogenesis in the rat nephritis models induced by anti-Thy-1.1 antibody, and since galectin-3 was coexistent with infiltrated macrophages or fibroblasts which are a kind of ECM-producing cells and are believed to induce the overproduction of ECM in the pre-fibrotic region, it was strongly suggested that galectin-3 is involved in the formation of fibrosis.

- 11 -

Example 2. Variation in galectin-3 expression in the
unilateral ureteral obstruction (UUO)-
treated rat interstitial fibrosis model

Female Sprague-Dawley rats (around 8 weeks old at
5 the start of the experiment) were used. Under anesthesia
with pentobarbital, complete ureteral obstruction of the
left kidney was produced by ligating the ureter with 4-0
silk suture at two points and cutting between the
ligatures. The left kidneys from each rat with UUO were
10 harvested as obstructed kidneys and the right kidney as
contralateral kidneys after perfused with phosphate
buffered saline under diethyl ether anesthesia after 10
days from the operation. Harvested kidneys were fixed
with 4 % (w/v) phosphate buffered paraformaldehyde for
15 overnight and transferred to 70% ethanol. Fixed kidneys
were embedded with paraffin and sectioned for immuno-
staining. The immunostaining of the tissue sections was
carried out by using an affinity-purified rabbit anti-
galectin-3 antibody as the primary antibody, a
20 peroxidase-labeled goat anti-rabbit antibody (Sigma) as
the secondary antibody, and DAB (Sigma: DAB Tablet) as
the chromogenic substrate.

The result of immunostaining of the tissue sections
is shown in Figure 2. The UUO model in which the
25 overproduction and the accumulation of ECM such as
collagen is observed in the interstitial region of the
urinary tubule is a well known model that induces
interstitial fibrosis (see Wright, E. J., et al., Lab.
Invest. (1996) 74: 528-537, Yamate, J., et al., Toxicol.
30 Pathol. (1998) 26: 793-801 and the like). In the
contralateral kidneys, a small quantity of galectin-3 is
present in the distal urinary tubule and the macula densa
region of the glomerulus, while in the obstructed
kidneys, infiltrated macrophage and fibroblasts were
35 coexistent with galectin-3 in the fibrotic region of the
tubulo-interstitium. This finding strongly suggested
that galectin-3 is involved in the formation of fibrosis

because galectin-3 was coexistent with infiltrated macrophage or fibroblasts which are a kind of ECM-producing cells and are believed to induce the overproduction of ECM in the fibrotic region.

5 Example 3. Suppressive activity of galectin-3 on the cellular death of rat mesangium cells

Rat mesangium cells were separated from Sprague-Dawley rats according to the method of Striker et al. (Striker, G. E., et al., Lab. Invest. (1985) 53; 123-128). The separated rat mesangium cells were cultured at 10 37°C in the presence of 5% CO₂ in the wells of a 96-well plate using an essential medium (DMEM/F12 (1:1) culture medium containing 60 µg/ml penicillin, 100 µg/ml streptomycin, manufactured by Gibco BRL) supplemented 15 with 10% fetal bovine serum. After culturing to semi-confluence, the cultured rat mesangium cells were washed with the essential medium, cultured for 2 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma), and then were further cultured for 1 to 20 4 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma) containing 0 or 50 µg/ml galectin-3 and 0 or 0.4 ng/ml TGF-β. On day 1, 2, 3, and 4 after the addition of galectin-3 and TGF-β, the amount of the cultured rat mesangium cells that survived in 25 their respective wells were measured using as an index the conversion from MTS tetrazolium (Cell Titer 96 Aqueous one solution manufactured by Promega) to formazan by the living cells.

The result is shown in Figure 3. In both of the 30 presence and the absence of TGF-β, galectin-3 was confirmed to suppress the cellular death of the rat mesangium cells, a kind of ECM-producing cells.

35 Example 4. Promoting effect of galectin-3 on the collagen type IV production by mesangium cells

Rat mesangium cells were separated in a similar

- 13 -

manner to that of Example 3. The separated mesangium cells were cultured at 37°C in the presence of 5% CO₂ in the wells of a 96-well plate using an essential medium (DMEM/F12 (1:1) culture medium containing 60 µg/ml penicillin, 100 µg/ml streptomycin, manufactured by Gibco BRL) supplemented with 10% fetal bovine serum. After culturing to confluence, the cultured rat mesangium cells were washed with the essential medium, cultured for 1 to 2 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma), and then were further cultured for 3 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma) containing 0, 10 or 30 µg/ml galectin-3 and 0, 0.1, 0.4 or 1.6 ng/ml TGF-β. On day 3 after the addition of galectin-3 and TGF-β, the amount of type IV collagen accumulated in the culture liquid was measured using a sandwich ELISA method that employed a goat anti-type IV collagen antibody as the immobilized antibody and a biotin-labeled goat anti-type IV collagen antibody (Chemicon) as the primary antibody. The amount of type IV collagen in the culture liquid of each well was normalized by dividing it by the amount of the living cells in each well determined in a similar manner to that described in Example 3.

The result is shown in Figure 4. It was confirmed that galectin-3 promotes the production and/or the accumulation of type IV collagen which is a kind of ECM, from the rat mesangium cells which is a kind of ECM-producing cells, in a similar manner to and in an additive manner with TGF-β.

Example 5. Inhibition of promotion by galectin-3 on collagen type IV production by rat mesangium cells, using a glycoprotein that inhibits galectin-3-binding

Rat mesangium cells were separated in a similar manner to that of Example 2. The separated rat mesangium cells were cultured at 37°C in the presence of 5% CO₂ in

- 14 -

wells of a 96-well plate using an essential medium (DMEM/F12 (1:1) culture medium containing 60 µg/ml penicillin, 100 µg/ml streptomycin, manufactured by Gibco BRL) supplemented with 10% fetal bovine serum. After
5 culturing to confluence, the cultured rat mesangium cells were washed with the essential medium, cultured for 1 to 2 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma), and then were further
10 cultured for 4 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma) containing 10 µg/ml of galectin-3 and 0, 0.1, 0.2, 0.5 or 1.5 mg/ml fetuin glycoprotein which is a substance known to inhibit
galectin-3 binding (see, for example, Sato, S. et al., J. Biol. Chem. (1992) 267: 6983-6990). On day 4 after the
15 addition of galectin-3 and fetuin, the amount of type IV collagen accumulated in the culture liquid of each well was measured using a sandwich ELISA method that employed a goat anti-type IV collagen antibody (Chemicon) as the
immobilized antibody and a biotin-labeled goat anti-type
20 IV collagen antibody (Chemicon) as the primary antibody. The amount of type IV collagen in the culture liquid of each well was normalized by dividing it by the amount of the living cells in each well determined in a similar
manner to that described in Example 3.

25 The result is shown in Figure 5. It was confirmed that a high molecular weight glycoprotein that inhibits galectin-3 binding suppresses the promotion of the production and/or the accumulation of type IV collagen which is a kind of ECM, from the rat mesangium cells
30 which are a kind of ECM-producing cells, by the addition of galectin-3.

Example 6. Inhibition, by galectin-3-binding
inhibiting sugar, of the effect of
galectin-3 on the promotion of collagen
type IV production by rat mesangium cells

35 Rat mesangium cells were separated in a similar

- 15 -

manner to that described in Example 3. The separated rat mesangium cells were cultured at 37°C in the presence of 5% CO₂ in the wells of a 96-well plate using an essential medium (DMEM/F12 (1:1) culture medium containing 60 µg/ml penicillin, 100 µg/ml streptomycin, manufactured by Gibco BRL) supplemented with 10% fetal bovine serum. After culturing to confluence, the cultured rat mesangium cells were washed in the essential medium, cultured for 1 to 2 days with the essential medium supplemented with 0.1% bovine serum albumin (Sigma), and then were further cultured for 2 days in the essential medium supplemented with 0.1% bovine serum albumin (Sigma) containing 0.4 µg/ml of galectin-3 and 0, 0.25, 0.5, 1 or 2 mM of lacto-n-fucopentaose I which is, a substance known to inhibit galectin-3 binding (LNFP-1, see, for example, Sato, S. et al., J. Biol. Chem. (1992) 267: 6983-6990). On day 2 after the addition of galectin-3 and LNFP-I, the amount of type IV collagen accumulated in the culture liquid of each well was measured using a sandwich ELISA method that employed a goat anti-type IV collagen antibody (Chemicon) as an immobilized antibody and a biotin-labeled goat anti-type IV collagen antibody (Chemicon) as a primary antibody. The amount of type IV collagen in the culture medium of each well was normalized by dividing it by the amount of the living cells in each well determined in a similar manner to that described in Example 4.

The result is shown in Figure 6. It was confirmed that a low molecular weight sugar that inhibits galectin-3 binding suppresses the promotion of the production and/or the accumulation of type IV collagen which is a kind of ECM, from the rat mesangium cells which are a kind of ECM-producing cells, by the addition of galectin-3.

As hereinabove described, it was shown that galectin-3 exhibits an increased expression during pathogenesis in the anti-Thy-1.1 antibody-induced rat

nephritis model, an animal model of mesangial proliferative glomerulonephritis, (Example 1), and thus it was suggested that galectin-3 is involved in the pathogenesis of mesangial proliferative glomerulonephritis. It was also demonstrated that in the anti-Thy-1.1 antibody-induced rat nephritis model and in the obstructed kidneys of the UUO rat model, galectin-3 is coexistent with infiltrated macrophage and fibroblasts in the pre-fibrotic or fibrotic region of the tubulointerstitium (Examples 1 and 2). This finding strongly suggested that galectin-3 is involved in the formation of fibrosis because galectin-3 was coexistent with infiltrated macrophage and/or fibroblasts, a kind of ECM-producing cells, that are believed to induce the overproduction of ECM in the pre-fibrotic or fibrotic region. It was also demonstrated that galectin-3 inhibits the cellular death of the mesangium cells, a kind of ECM-producing cells (Example 3), and that it promotes the production and/or the accumulation of ECM from the ECM-producing cells (Example 4). It was further shown that a substance that inhibits the biological activity of galectin-3 suppresses the promotion of the production and/or the accumulation of ECM from ECM-producing cells by galectin-3 (Examples 5 and 6).

INDUSTRIAL APPLICABILITY

A pharmaceutical composition of the present invention comprising a compound that controls the actions of galectin-3 as active ingredient can be clinically applicable as a therapeutic or preventive agent for glomerular nephritis, diabetic nephropathy or tissue fibrosis.

CLAIMS

1. A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound having an inhibitory effect on the biological activity of galectin-3.
2. The pharmaceutical composition according to claim 1, wherein the biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.
3. The pharmaceutical composition according to claim 1 which exhibits an inhibitory effect on glomerular nephritis, diabetic nephropathy or tissue fibrosis of which cause is the overproduction and the accumulation of extracellular matrix.
4. The pharmaceutical composition according to claim 3, wherein the biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.
5. The pharmaceutical composition according to any of claims 1 to 4, wherein the compound having an inhibitory effect on the biological activity of galectin-3 is an anti-galectin 3 antibody.
6. The pharmaceutical composition according to any of claims 1 to 4, wherein the compound having an inhibitory effect on the biological activity of galectin-3 is an inhibitor of galectin 3 binding.
7. The pharmaceutical composition according to any of claims 1 to 4, wherein the compound having an inhibitory effect on the biological activity of galectin-3 is a compound that inhibits the incorporation of galectin 3 into the cell.
8. The pharmaceutical composition according to any of claims 1 to 4, wherein the compound that inhibits the biological activity of galectin-3 is a compound that modulates the transfer of galectin 3 into the nucleus.

9. The pharmaceutical composition according to any of claims 1 to 4, wherein the compound that inhibits the biological activity of galectin-3 is a compound that inhibits the physiological activity of galectin 3 in the nucleus or the cytoplasm.

10. The pharmaceutical composition according to any of claims 1 to 4, wherein the compound that inhibits the biological activity of galectin-3 is a compound that modulates the expression or secretion of galectin 3.

11. The pharmaceutical composition according to any one of claims 1 to 10, which is a therapeutic or preventive agent.

12. The pharmaceutical composition according to any of claims 3 to 11, wherein the glomerular nephritis, diabetic nephropathy or tissue fibrosis is glomerular nephritis, diabetic nephropathy or tissue fibrosis, respectively, caused by the abnormal proliferation of mesangium cells.

13. The use of a compound having an inhibitory effect on the biological activity of galectin-3, for the production of a pharmaceutical composition for inhibition of the overproduction and the accumulation of extracellular matrix.

14. The use according to claim 13, wherein the biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.

15. The use according to claim 13, for treatment of glomerular nephritis, diabetic nephropathy or tissue fibrosis of which cause is the overproduction and the accumulation of extracellular matrix.

16. The use according to claim 15, wherein the biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.

17. The use according to any of claims 13 to 16, wherein the compound having an inhibitory effect on the

biological activity of galectin-3 is an anti-galectin 3 antibody.

18. The pharmaceutical composition according to any of claims 13 to 16, wherein the compound having an
5 inhibitory effect on the biological activity of galectin-3 is an inhibitor of galectin 3 binding.

19. The pharmaceutical composition according to any of claims 13 to 16, wherein the compound having an
10 inhibitory effect on the biological activity of galectin-3 is a compound that inhibits the incorporation of galectin 3 into the cell.

20. The pharmaceutical composition according to any of claims 13 to 16, wherein the compound that inhibits
15 the biological activity of galectin-3 is a compound that modulates the transfer of galectin 3 into the nucleus.

21. The pharmaceutical composition according to any of claims 13 to 16, wherein the compound that inhibits
20 the biological activity of galectin-3 is a compound that inhibits the physiological activity of galectin 3 in the nucleus or the cytoplasm.

22. The pharmaceutical composition according to any of claims 13 to 16, wherein the compound that inhibits
the biological activity of galectin-3 is a compound that modulates the expression or secretion of galectin 3.

23. The use according to any one of claims 13 to
25 22, which is for a therapeutic or preventive use.

24. The use according to any of claims 15 to 23,
wherein the glomerular nephritis, diabetic nephropathy or
30 tissue fibrosis is glomerular nephritis, diabetic nephropathy or tissue fibrosis, respectively, caused by
the abnormal proliferation of mesangium cells.

25. A method for inhibition of the overproduction
and the accumulation of extracellular matrix, said method
35 comprising administering a compound having an inhibitory effect on the biological activity of galectin-3, to a
subject which needs said inhibition.

26. The method according to claim 25, wherein the

biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.

27. The method composition according to claim 25 for inhibition of glomerular nephritis, diabetic nephropathy or tissue fibrosis of which cause is the overproduction and the accumulation of extracellular matrix.

28. The method according to claim 27 wherein the biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.

29. The method according to any of claims 25 to 28, wherein the compound having an inhibitory effect on the biological activity of galectin-3 is an anti-galectin 3 antibody.

30. The method according to any of claims 25 to 28, wherein the compound having an inhibitory effect on the biological activity of galectin-3 is an inhibitor of galectin 3 binding.

31. The method according to any of claims 25 to 28, wherein the compound having an inhibitory effect on the biological activity of galectin-3 is a compound that inhibits the incorporation of galectin 3 into the cell.

32. The method according to any of claims 25 to 28, wherein the compound that inhibits the biological activity of galectin-3 is a compound that modulates the transfer of galectin 3 into the nucleus.

33. The method according to any of claims 25 to 28, wherein the compound that inhibits the biological activity of galectin-3 is a compound that inhibits the physiological activity of galectin 3 in the nucleus or the cytoplasm.


34. The method according to any of claims 25 to 28, wherein the compound that inhibits the biological activity of galectin-3 is a compound that modulates the expression or secretion of galectin 3.

35. The method according to any one of claims 25 to 34, which is for therapeutic or preventive treatment.

5 36. The method according to any of claims 27 to 35, wherein the glomerular nephritis, diabetic nephropathy or tissue fibrosis is glomerular nephritis, diabetic nephropathy or tissue fibrosis, respectively, caused by the abnormal proliferation of mesangium cells.


1/6

Fig.1




2/6

Fig.2




3/6

Fig.3




4/6

Fig. 4




5/6

Fig. 5



6/6

Fig. 6





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, 38/17, 31/70, A61P 13/12	A3	(11) International Publication Number: WO 00/07624 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/JP99/04238 (22) International Filing Date: 5 August 1999 (05.08.99) (30) Priority Data: 10/233499 6 August 1998 (06.08.98) JP (71) Applicant (for all designated States except US): TEIJIN LIMITED [JP/JP]; 6-7, Minamihommachi 1-chome, Chuo-ku, Osaka-shi, Osaka 541-0054 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): SASAKI, Satoshi [JP/JP]; Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). SUMI, Yoshihiko [JP/JP]; Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). HUGHES, Reginald, Colin [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London, Greater London NW7 1AA (GB). (74) Agents: ISHIDA, Takashi et al.; A. Aoki, Ishida & Associates, Toranomom 37 Mori Building, 5-1, Toranomom 3-chome, Minato-ku, Tokyo 105-8423 (JP).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 22 June 2000 (22.06.00)
(54) Title: PHARMACEUTICAL COMPOSITION HAVING INHIBITORY EFFECT ON OVERPRODUCTION AND ACCUMULATION OF EXTRACELLULAR MATRIX (57) Abstract <p>A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biological activity of galectin-3, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, diabetic nephropathy or tissu fibrosis, as well as the use of said compound for the production of pharmaceuticals for the above-mentioned use, and a method for inhibition of the overproduction and accumulation of the extracellular matrix.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PCT/JP 99/04238

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/395 A61K38/17 A61K31/70 A61P13/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	OCHIENG J ET AL: "Regulation of cellular adhesion to extracellular matrix proteins by galectin-3." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1998 MAY 29) 246 (3) 788-91. , XP002131316 the whole document	1-36
A	HENRICK K ET AL: "Evidence for subsites in the galectins involved in sugar binding at the nonreducing end of the central galactose of oligosaccharide ligands: sequence analysis, homology modeling and mutagenesis studies of hamster galectin-3." GLYCOBIOLOGY, (1998 JAN) 8 (1) 45-57. , XP000876954 the whole document	1-36

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

23 February 2000

Date of mailing of the international search report

16/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

Int'l. Application No.

PCT/JP 99/04238

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PROBSTMEIER R ET AL: "Galectin-3, a beta-galactoside-binding animal lectin, binds to neural recognition molecules." JOURNAL OF NEUROCHEMISTRY, (1995 JUN) 64 (6) 2465-72. , XP000876914 the whole document</p>	1-36
A	<p>LIU F.T ET AL: "Modulation of functional properties of galectin -3 by monoclonal antibodies binding to the non-lectin domains." BIOCHEMISTRY, (1996 MAY 14) 35 (19) 6073-9. , XP002131317 cited in the application the whole document</p>	1-36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 99/04238

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 25-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)